Last Updated : June 27, 2024
Details
FilesGeneric Name:
atogepant
Project Status:
Active
Therapeutic Area:
Migraine, prevention
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Qulipta
Project Line:
Reimbursement Review
Project Number:
SR0817-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of chronic migraine in adults with 15 headache days per month (among which 8 days are considered to be migraine days) and who have previously failed, are intolerant to, or have a contraindication to at least two migraine preventive therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The prevention of migraine in adults who have at least 4 migraine days per month.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 30-Oct-23 |
|---|---|
| Call for patient/clinician input closed | 22-Dec-23 |
| Clarification: - Patient input submission received from the Canadian Migraine Society and Migraine Canada | |
| Submission received | 21-Dec-23 |
| Submission accepted | 12-Jan-24 |
| Review initiated | 15-Jan-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 02-Apr-24 |
| Deadline for sponsors comments | 11-Apr-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 09-May-24 |
| Expert committee meeting (initial) | 22-May-24 |
| Draft recommendation issued to sponsor | 04-Jun-24 |
| Draft recommendation posted for stakeholder feedback | 13-Jun-24 |
| End of feedback period | 27-Jun-24 |
| Clarification: - Reconsideration: minor revisions requested by sponsor | |
Files
Last Updated : June 27, 2024